- Home
- SRG vs INBX Comparison
SRG vs INBX Comparison
Compare SRG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- INBX
- Stock Information
- Founded
- SRG 2014
- INBX 2010
- Country
- SRG United States
- INBX United States
- Employees
- SRG N/A
- INBX N/A
- Industry
- SRG Real Estate Investment Trusts
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- INBX Health Care
- Exchange
- SRG Nasdaq
- INBX Nasdaq
- Market Cap
- SRG 238.6M
- INBX 218.9M
- IPO Year
- SRG 2015
- INBX 2020
- Fundamental
- Price
- SRG $3.70
- INBX $13.25
- Analyst Decision
- SRG
- INBX Hold
- Analyst Count
- SRG 0
- INBX 1
- Target Price
- SRG N/A
- INBX N/A
- AVG Volume (30 Days)
- SRG 185.1K
- INBX 97.1K
- Earning Date
- SRG 11-12-2024
- INBX 11-14-2024
- Dividend Yield
- SRG N/A
- INBX 6.53%
- EPS Growth
- SRG N/A
- INBX N/A
- EPS
- SRG N/A
- INBX 119.38
- Revenue
- SRG $56,359,000.00
- INBX $1,568,000.00
- Revenue This Year
- SRG N/A
- INBX N/A
- Revenue Next Year
- SRG N/A
- INBX N/A
- P/E Ratio
- SRG N/A
- INBX $0.11
- Revenue Growth
- SRG N/A
- INBX 19.24
- 52 Week Low
- SRG $3.61
- INBX $10.80
- 52 Week High
- SRG $9.87
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SRG 26.97
- INBX 43.12
- Support Level
- SRG $3.70
- INBX $12.60
- Resistance Level
- SRG $3.86
- INBX $13.97
- Average True Range (ATR)
- SRG 0.13
- INBX 0.96
- MACD
- SRG -0.01
- INBX -0.01
- Stochastic Oscillator
- SRG 4.90
- INBX 36.48
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.